BioCentury | Dec 17, 2001
Company News

Cytogen, Pluvita deal

...subsidiary AxCell Biosciences will identify full-length peptides that bind to a protein-based drug target from Pluvita...
...the human proteome and determine affinities of compound binding to the isolated peptides. Last month, Pluvita...
...pathway database for drug discovery research (see BioCentury, Dec. 3). Cytogen Corp. (CYTO), Princeton, N.J. Pluvita Corp....
BioCentury | Dec 11, 2001
Company News

Cytogen, Pluvita drug target deal

...CYTO subsidiary AxCell will identify full-length peptides that bind to a protein-based drug target from Pluvita...
...human proteome and will determine affinities of compound binding with the isolated peptides. Last month, Pluvita...
BioCentury | Dec 3, 2001
Company News

Cytogen, Pluvita deal

...and is distributed by partner InforMax Inc. (INMX, Rockville, Md.). Cytogen Corp. (CYTO), Princeton, N.J. Pluvita Corp....
BioCentury | Nov 28, 2001
Company News

CYTO, INMX, Pluvita proteomics deal

Pluvita (Bethesda, Md.) will use the ProChart signal transduction pathway database for its drug discovery research. ProChart was developed by Cytogen (CYTO) subsidiary AxCell Biosciences and is distributed by partner InforMax (INMX). BC Staff...
BioCentury | Oct 8, 2001
Company News

Diogenics Inc., Pluvita deal

...systems to identify and validate clinically relevant gene and protein targets in steroid hormone-responsive diseases. Pluvita...
...to disease targets, model systems, functional genomics and proteomics capabilities. Diogenics Inc. , Irvine, Calif. Pluvita Corp....
BioCentury | Oct 8, 2001
Company News

Pluvita management update

Pluvita Corp. , Bethesda, Md. Business: Metabolic Hired: Cynthia French as SVP of R&D, formerly president of Diogenics WIR Staff...
BioCentury | Oct 3, 2001
Company News

Pluvita acquires Diogenics

...biosystems to identify and validate clinically relevant gene and protein targets in steroid hormone-responsive diseases. Pluvita...
Items per page:
1 - 7 of 7
BioCentury | Dec 17, 2001
Company News

Cytogen, Pluvita deal

...subsidiary AxCell Biosciences will identify full-length peptides that bind to a protein-based drug target from Pluvita...
...the human proteome and determine affinities of compound binding to the isolated peptides. Last month, Pluvita...
...pathway database for drug discovery research (see BioCentury, Dec. 3). Cytogen Corp. (CYTO), Princeton, N.J. Pluvita Corp....
BioCentury | Dec 11, 2001
Company News

Cytogen, Pluvita drug target deal

...CYTO subsidiary AxCell will identify full-length peptides that bind to a protein-based drug target from Pluvita...
...human proteome and will determine affinities of compound binding with the isolated peptides. Last month, Pluvita...
BioCentury | Dec 3, 2001
Company News

Cytogen, Pluvita deal

...and is distributed by partner InforMax Inc. (INMX, Rockville, Md.). Cytogen Corp. (CYTO), Princeton, N.J. Pluvita Corp....
BioCentury | Nov 28, 2001
Company News

CYTO, INMX, Pluvita proteomics deal

Pluvita (Bethesda, Md.) will use the ProChart signal transduction pathway database for its drug discovery research. ProChart was developed by Cytogen (CYTO) subsidiary AxCell Biosciences and is distributed by partner InforMax (INMX). BC Staff...
BioCentury | Oct 8, 2001
Company News

Diogenics Inc., Pluvita deal

...systems to identify and validate clinically relevant gene and protein targets in steroid hormone-responsive diseases. Pluvita...
...to disease targets, model systems, functional genomics and proteomics capabilities. Diogenics Inc. , Irvine, Calif. Pluvita Corp....
BioCentury | Oct 8, 2001
Company News

Pluvita management update

Pluvita Corp. , Bethesda, Md. Business: Metabolic Hired: Cynthia French as SVP of R&D, formerly president of Diogenics WIR Staff...
BioCentury | Oct 3, 2001
Company News

Pluvita acquires Diogenics

...biosystems to identify and validate clinically relevant gene and protein targets in steroid hormone-responsive diseases. Pluvita...
Items per page:
1 - 7 of 7